Loading data for NEO — first visit, this takes a few seconds.

Alerta

NeoGenomics Inc. (NEO)

NasdaqCM: NEO · Precio en tiempo real · USD

16.41

-0.57 (-3.36%)

Al cierre: Aug 26, 2026, 3:59 PM

El precio, las cifras principales y las últimas noticias, en un solo sitio.

-3.36% (1D)

Precio de compra	11.97
Capitalización de mercado	2.11B
Ingresos (TTM)	766.29M
Beneficio neto (TTM)	-51.88M
	1.73
	-0.38
	n/a
	47.75
P/B (TTM)	2.67
P/S (TTM)	2.79
Fecha de resultados	Apr 29, 2025

Precio de venta	20.49
Volumen	1,093,873
Volumen medio (20D)	2,796,361
Abierto	16.75
Anterior Cerrar	16.98
Rango del día	16.28 - 16.80
Rango de 52 semanas	6.41 - 17.08
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de NEO

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing se...

[Leer más]

Industria Diagnostics & Research

Sector Healthcare

IPO Fecha Mar 16, 2004

Empleados 2,500

Bolsa de Valores NasdaqCM

Símbolo bursátil NEO

Sitio web https://www.neogenomics.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de NeoGenomics fueron 727.33M, un aumento de 10.11% en comparación con 660.57M del año anterior. Las ganancias fueron -108.03M, un aumento de 37.22%.

Estados financieros

Sorpresa de resultados

NeoGenomics ha publicado sus resultados trimestrales en Jul 28, 2026:

Ingresos de $201.66M falla las estimaciones por $0, con 11.21% Crecimiento interanual.
EPS de 0.05 supera las estimaciones en 0.02, con 66.67% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que NeoGenomics Inc. publique sus resultados el Apr 29, 2025, antes de que se abra el mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

3 días hace · Zacks

NeoGenomics, Inc. (NEO) Hits Fresh High: Is There Still Room to Run?

NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

6 días hace · StockStory

3 Unprofitable Stocks Walking a Fine Line

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital ...

2 semanas hace · StockStory

3 Stocks Under $50 with Open Questions

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some ...

2 semanas hace · Simply Wall St.

NeoGenomics (NEO) Is Up 8.4% After Q2 Profit Return And Raised 2026 Outlook – Has The Bull Case Changed?

In July 2026, NeoGenomics, Inc. reported second-quarter 2026 results showing revenue of US$201.66 million and net income of US$2.24 million, compared with revenue of US$181.33 million and a net loss o...

3 semanas hace · Zacks

NeoGenomics, Inc. (NEO) Hit a 52 Week High, Can the Run Continue?

NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Página 1 de 2

NeoGenomics Inc. (NEO)